To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Trial details
- Registry ID
- NCT05908084
- Drugs studied
- AVF, Acellular Tissue Engineered Vessel (ATEV)
TrialRedline tracks 6 clinical trials sponsored by Humacyte, Inc.: 3 Phase 3, 1 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084 | AVF, Acellular Tissue Engineered Vessel (ATEV) | Active not recruiting | 2027-06Estimated |
| Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisNCT03183245 | Arteriovenous fistula (AVF), Hemodialysis, Human Acellular Vessel (HAV) | Completed | 2024-04-22Actual |
| Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisNCT02644941 | Human Acellular Vessel (HAV), ePTFE graft | Completed | 2019-05Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418 | Acellular Tissue Engineered Vessel (ATEV) | Completed | 2023-09-19Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for DialysisNCT04135417 | HAV | Completed | 2021-05-15Actual |
| Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADNCT02887859 | Human Acellular Vessel (HAV) | Completed | 2020-12Actual |
Names as written in the registry records.
NCT03005418 · Humacyte, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: ATEV Primary Patency - Extremity Group (Non-iatrogenic) Measure: Rate of ATEV Infection - Extremity Group (Non-iatrogenic) Measure: Number of Participants With Adverse Events for Each Severity Grade - Extremity Group (Non-iatrogenic). After: Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the All HAV Group Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the Extremity Community-Acquired Trauma Subgroup.
Before: 51 participants (actual). After: 72 participants (actual).
Before: 30 Jun 2023. After: 19 Sep 2023.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: 150 participants (planned). After: 121 participants (actual).
Before: Oct 2026. After: Jun 2027.
Before: Recruiting. After: Active not recruiting.